| News

Versameb raises 6 million Swiss francs

17.07.2020

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Using revenues obtained from a seed financing round totaling 6 million Swiss francs, Versameb is planning to bring its VERSagile platform to the clinical development stage by the end of 2021, as detailed in a press release. Versameb has developed VERSagile in order to program mRNA sequences for improved therapeutic efficacy. To this end, a molecular algorithm developed by the Basel-based company is used. The molecules developed in this fashion are designed to be used in the areas of dermatology and oncology, as well in the field of myology, the study of muscle diseases.

The potential of the Versameb approach was recognized very early on by the investment and innovation promotion agency Basel Area Business & Innovation, which supported the company in 2017/18 by way of BaseLaunch, the organization’s biotech accelerator and incubator. Versameb has now set its sights on driving forward the development of the company. To this end, it has strengthened its management team with the addition of Klaas P. Zuideveld, who has been appointed Chief Development Officer (CDO). He will bring a “rare combination” of scientific excellence and management experience to the role, according to Friedrich Metzger, Co-Founder and CEO of Versameb, who was quoted in the press release.

With Versameb having already achieved important milestones with the VERSagile platform, Dr. Reinhard Ambros, Chairman of the Board of Versameb and former Head of the Novartis Venture Fund, is delighted to see “that the company is attracting excellent talent to perform on our strategic and operational goals and that it is enjoying strong support from its investors”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area has ever more to offer investors
Basel Area Business & Innovation, Innovation, Invest

Basel Area has ever more to offer investors

The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than...

Read More
Basel researchers developing universal cancer therapy
Basel Area Business & Innovation, Innovation, Invest

Basel researchers developing universal cancer therapy

Researchers from Basel are working on the development of a therapy in which pre-prepared immune cells can be used to...

Read More
Opterion Health AG moving to Muttenz
Basel Area Business & Innovation, Innovation, Invest

Opterion Health AG moving to Muttenz

Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from...

Read More
Evolva brings natural sugar blocker to market
Basel Area Business & Innovation, Innovation, Invest

Evolva brings natural sugar blocker to market

The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be...

Read More
Holmusk opens new office in Basel
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Holmusk opens new office in Basel

Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis....

Read More
Zifo RnD Solutions coming to Basel
Basel Area Business & Innovation, Innovation, Invest

Zifo RnD Solutions coming to Basel

Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo...

Read More
1 2 3 39

Do you have a question? We'd like to hear from you.